The Food and Drug Administration today approved Biogen’s Aduhelm to treat Alzheimer’s disease, the first new treatment approved for the disease since 2003. The drug was approved using the accelerated approval pathway, which is typically used when a drug for a serious or life-threatening illness is found to have a meaningful therapeutic advantage over existing treatments.

Aduhelm represents a first-of-its-kind treatment approved for Alzheimer’s disease in that it is the first therapy that targets the disease’s fundamental pathophysiology. As part of the accelerated approval provisions, which enables Alzheimer’s patients’ earlier access to treatment, FDA is requiring Biogen to conduct a new randomized, controlled clinical trial to verify the drug’s clinical benefit. In the event the trial fails to verify the drug’s clinical benefit, FDA may withdraw its approval.

Related News Articles

Headline
Commenting today on the Centers for Medicare & Medicaid Services’ home health prospective payment system proposed rule for calendar year 2022, AHA…
Headline
The Centers for Medicare & Medicaid Services late today issued a proposed rule to update skilled nursing facility payment rates for fiscal year 2022. The…
Headline
The Centers for Medicare & Medicaid Services last month extended to April 1 the deadline for eligible hospitals to submit calendar year 2020 electronic…
Headline
The National Quality Forum’s Measure Applications Partnership recently initiated its statutorily required annual review of the quality measures that the…
Headline
The Centers for Medicare & Medicaid Services today announced that it is extending the third quarter 2020 data submission deadlines for several of its…
Headline
The Centers for Medicare & Medicaid Services on Dec. 1 will retire Hospital Compare and seven other health care quality compare websites, whose content has…